Abstract: The present invention provides a method for preparing a drug composition, which includes steps of dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug into a solvent to form a mixture solution, and the pH value of the mixture solution is adjusted to a range without precipitating the hydrophilic drug(s) and the hydrophobic drug(s), wherein the amphiphilic chitosan derivative is modified by a plurality of hydrophilic group(s) and a plurality of hydrophobic group(s); and after stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH value of the mixture solution is between pH 6 to 7. The hydrophilic drug(s) and the hydrophobic drug(s) are encapsulated simultaneously by one-pot synthesis, and the protein could be modified by one-pot synthesis to provide a drug composition with multiple functions.

Abstract: A nano-photoacoustic imaging agent is disclosed. The nano-photoacoustic imaging agent includes a porous carrier and a gold filling material embedded in the porous carrier. A method for the preparation of the nano-photoacoustic imaging agent is also provided.

Abstract: A gel composition and method of manufacturing the same is discussed. The gel composition includes a plurality of chitosan spheres, an alkaline chitosan stabilizing agent, a chitosan decomposition enzyme and a drug. The chitosan spheres are formed by chitosan self-assembly. The alkaline chitosan stabilizing agent connects the chitosan spheres to form a gel body. The chitosan decomposition enzyme scatters in the gel body and decomposes the gel composition at a temperature of 20 to 40 degree Celsius. The drug scatters in the gel body.

Abstract: The present invention relates to a thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof. The thermosensitive injectable glaucoma drug carrier gel comprises: a polymer substrate comprising chitosan with hydrophilic and hydrophobic modification; an additive dispersed in the substrate, wherein the additive comprises a water/fat soluble glaucoma drug, a preservative, a solvent selected from glycerol, dimethyl sulfoxide (DMSO), ethanol, glycol or any combination thereof, and a basic structural stabilizer; and water.

Abstract: The present invention relates to a novel injectable delivery system for stem cell therapy, which comprises a thermo-sensitive amphiphlic chitosan nanogel. Therefore, the invention provides a method for repairing a tissue damage of a subject using the amphiphlic chitosan nanogel served as a carrier for delivering the stem cells to the damaged tissue. This invention also provides a method for sustaining the growth of stem cells using the amphiphlic chitosan nanogel served as a niche or scaffold.

Abstract: The present invention discloses a dissoluble PDMS-modified p(HEMA-MAA) amphiphilic copolymer and the method of fabricating the same. The amphiphilic copolymer of the present invention is fabricated via chemically bonding HEMA, MAA, and poly(dimethylsiloxane), bis(3-aminopropyl) terminated (PDMS) in aqueous solution. The PDMS-modified p(HEMA-MAA) amphiphilic copolymer can be dissolved completely in polar solvents, particularly alcohol solvents, to facilitate subsequent processing. The amphiphilic copolymer features adjustable hydrophobic-hydrophilic properties and exhibits excellent biocompatibility. Thus, it can be utilized in a number of advanced applications, including anti-fouling and drug delivery.

Abstract: The present invention discloses a dissoluble PDMS-modified p(HEMA-MAA) amphiphilic copolymer and the method of fabricating the same. The amphiphilic copolymer of the present invention is fabricated via chemically bonding HEMA, MAA, and poly(dimethylsiloxane), bis(3-aminopropyl) terminated (PDMS) in aqueous solution. The PDMS-modified p(HEMA-MAA) amphiphilic copolymer can be dissolved completely in polar solvents, particularly alcohol solvents, to facilitate subsequent processing. The amphiphilic copolymer features adjustable hydrophobic-hydrophilic properties and exhibits excellent biocompatibility. Thus, it can be utilized in a number of advanced applications, including anti-fouling and drug delivery.

Abstract: A nano-photoacoustic imaging agent is disclosed. The nano-photoacoustic imaging agent includes a porous carrier and a gold filling material embedded in the porous carrier. A method for the preparation of the nano-photoacoustic imaging agent is also provided.

Abstract: The present invention discloses a dissoluble PDMS-modified p(HEMA-MAA) amphiphilic copolymer and the method of fabricating the same. The amphiphilic copolymer of the present invention is fabricated via chemically bonding HEMA, MAA, and poly(dimethylsiloxane), bis (3-aminopropyl) terminated (PDMS) in aqueous solution. The PDMS-modified p(HEMA-MAA) amphiphilic copolymer can be dissolved completely in polar solvents, particularly alcohol solvents, to facilitate subsequent processing. The amphiphilic copolymer features adjustable hydrophobic-hydrophilic properties and exhibits excellent biocompatibility. Thus, it can be utilized in a number of advanced applications, including anti-fouling and drug delivery.

Abstract: The present invention discloses a drug-carrying contact lens and a method for fabricating the same. The drug-carrying contact lens comprises a contact lens containing at least one amphiphatic hybrid nanocarrier carrying drug molecules. According to the heat or light sensitivity of the drug molecule, the present invention respectively fabricates an encapsulation-type drug-carrying contact lens and a drug-soaking type drug-carrying contact lens. The present invention uses a highly-biocompatible amphiphatic hybrid nanocarriers having superior drug encapsulation capability to wrap the drug molecules. Thereby, the drug molecules are uniformly distributed in the contact lens and can be gradually and locally released to the eye of the user wearing the contact lens. Therefore, the present invention can prevent or cure ocular diseases with the loss and side effects of the drug being reduced.

Abstract: A drug carrier is provided with a structure of a lipid shell enclosing aqueous micelles. The lipid shell includes lipid and emulsifier, in which the emulsifier encloses the lipid. The components of the aqueous micelles are phospholipids and amphiphilic chitosan, and the aqueous micelles enclose an aqueous solution containing a drug. Furthermore, the method of preparing the drug carrier is also provided. Therefore, with the pharmaceutical advantages of lipid-based nanoparticle included low drug leakage and the ability of to overcome the multiple drug resistance, this new formulation were further incorporated with the chitosan and featured with high payload efficiency. The features could enhance intracellular concentration of anti-cancer drug and oral bioavailability.

Abstract: The present invention relates to a novel injectable delivery system for stem cell therapy, which comprises a thermo-sensitive amphiphlic chitosan nanogel. Therefore, the invention provides a method for repairing a tissue damage of a subject using the amphiphlic chitosan nanogel served as a carrier for delivering the stem cells to the damaged tissue. This invention also provides a method for sustaining the growth of stem cells using the amphiphlic chitosan nanogel served as a niche or scaffold.

Abstract: The present invention discloses a drug-carrying contact lens and a method for fabricating the same. The drug-carrying contact lens comprises a contact lens containing at least one amphiphatic hybrid nanocarrier carrying drug molecules. According to the heat or light sensitivity of the drug molecule, the present invention respectively fabricates an encapsulation-type drug-carrying contact lens and a drug-soaking type drug-carrying contact lens. The present invention uses a highly-biocompatible amphiphatic hybrid nanocarriers having superior drug encapsulation capability to wrap the drug molecules. Thereby, the drug molecules are uniformly distributed in the contact lens and can be gradually and locally released to the eye of the user wearing the contact lens. Therefore, the present invention can prevent or cure ocular diseases with the loss and side effects of the drug being reduced.

Abstract: The present invention discloses a magnetically-controllable nanometric porous drug carrier, wherein an organic or inorganic matrix is used to carry the drug, and wherein magnetic nanoparticles having magnetosensitivity are used to encapsulate the surface of the matrix and seal the drug inside the matrix. An external magnetic field is used to control the removal rate of the magnetic nanoparticles and control the behavior and rate of drug release.

Abstract: A hollow sphere from amphiphilic chitosan derivatives and a method of preparing an amphiphilic chitosan derivative complex for medical use are disclosed, and the hollow sphere from amphiphilic chitosan derivatives comprises: chitosan derivatives represented by the following formula (I), which self-assemble and form a hollow sphere in a solvent; wherein, each R1 is independently hydrogen, C1˜C4 alkyl, C1˜C6 carboxyl, sulfate group, or phosphate group, each R2 is independently hydrogen, C1˜C12 alkyl, C1˜C6 carboxyl, or C2˜C12 acyl group, and m is an integer of 100-2000.

Abstract: The present invention provides a carrier component. The carrier component includes a carrier core body including a dispersive object and a dualistic self-assembly material for encapsulating the dispersive object, wherein the dualistic self-assembly material has an electric charge; and a first shell layer having an electric charge opposite to the electric charge of the dualistic self-assembly material, and coating the carrier core body, and thus avoids inactivation of a medicine, eliminates medicine leakage and reduces medicine releasing. The present invention further provides a method for forming a carrier component.

Abstract: The invention discloses the synthesis of a new-type chitosan-based hybrid macromolecule and a method for producing or using the macromolecule. This macromolecule comprises an amphiphatic chitosan and a silicon-based coupling agent that is anchored by a chemical bonding. The method for producing the hybrid macromolecule can be easily operated under ambient environment. The produced macromolecule can be self-assembled in an aqueous environment to form a nanocarrier, and has the ability to efficiently encapsulate drugs for a subsequent sustained release purpose. This self-assembled hybrid nanocarrier demonstrated features of excellent biocompatibility, drug loading ability and cellular uptake efficiency.

Abstract: A stable and taste masked pharmaceutical dosage form includes porous apatite grains and a drug entrapped in pores of said grains, wherein said grains have a size of 0.1-1000 ?m and said pores of said grains have an opening of 0.5-300 nm. A process for preparing the stable and taste masked pharmaceutical dosage form is also disclosed.

Abstract: An injectable smart gel and a method for fabricating the same are disclosed. A basic structural stabilizer/polymeric electrolyte and a diluting solution are added to a modified chitosan to regulate the chitosan solution to have a pH value closing to that of the human body and form a flowable chitosan sol. The flowable chitosan sols formed thereby are respectively converted into inflowable chitosan gels via increasing the temperature thereof to the human body temperature, and via adding calcium ion or regulating the chitosan sol into an acidic solution. The injectable smart gel fabricated thereby is injectable and able to function as a carrier of magnetism-sensitive medicine-containing nanocapsules. The medicine can be released to the injectable smart gel with an external non-contact force, such as a magnetic field, an electric field or an ultrasonic wave, for long-acting and multi-stage medicine delivery. The present invention is very useful in biomedical engineering.

Abstract: Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring the concentration and distribution of the released drugs and/or active compounds injected separately into a target site of a subject.